Novartis CAR-T cancer therapy wins expert support for FDA approval
Novartis’ novel CAR-T cancer therapy is a big step closer to reaching patients after outside experts convened by the FDA voted 10-0 to recommend approval.
Novartis’ groundbreaking CAR-T cancer therapy is one big step closer to reaching patients.
A panel of outside experts convened by the FDA voted 10-0 Wednesday to recommend the approval of Novartis’ CAR-T therapy, called CTL019, for the treatment of children and young adults with advanced leukemia. The vote marks a pivotal milestone for this class of experimental treatment. The FDA is expected to make a
